• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » The top 5 MassDevice stories of the week — July 31, 2020

The top 5 MassDevice stories of the week — July 31, 2020

July 31, 2020 By Chris Newmarker

MassDevice Top Five medtech stories weekThe past week has seen a slew of Q2 earnings reports from medical device companies — and the picture overall hasn’t been pretty amid the COVID-19 pandemic.

Still, medtech CEOs during their earnings calls said they’re starting to see some signs of hospital procedures recovering a bit even as the southern U.S. deals with a coronavirus wave. Some of the top MassDevice stories this week actually involved companies providing more solutions to improve management of the pandemic.

Want to hear more about the week’s top news? Executive editor Chris Newmarker and Tom Salemi will discuss during our DeviceTalks Weekly podcast. Without further ado, here’s this week’s MassDevice Top Five:

5. A few bright spots amid the COVID-19 financial toll

Dexcom (NSDQ:DXCM) proved to be one of the few bright spots among medtech Q2 earnings reports, blowing away the Wall Street consensus forecast as it successfully pivoted to making its continuous glucose monitors available to U.S. hospitals during the crisis. The move helped boost Dexcom sales up by more than a third.

Hologic (NSDQ:HOLX) meanwhile saw a 3.5% sales dip — but a 45.3% boost in profits fueled by its widely-used SARS-CoV-2 assays.

Among other top medical device companies, some managed to perform better than expectations on The Street, but the Q2 year-over-year sales declines were still tough: a better-than-expected –24.3% for Stryker (NYSE:SYK), a better-than-expected –23.9% for  Boston Scientific (NYSE:BSX), a worse-than-expected –4.1% for Baxter (NYSE:BAX), a better-than-expected –13.1% for Teleflex (NYSE:TFX), a worse-than-expected nearly –30% for Smith+Nephew (LON:SN), and a -21% for GE Healthcare amid mixed-bag results for all of General Electric (NYSE:GE).

Read the full story about Dexcom. 

4. Innovation continues at Smith+Nephew

The orthopedic device space has been especially hard-hit by COVID-19. But count Smith+Nephew (NYSE:SNN) among the companies continuing to launch new products. The British medtech giant this week launched its RI Hip Navigation system for total hip arthroplasty. The technology is designed to maximize accuracy and reproducibility to deliver patient-specific component alignment for surgeons when assessing individual total hip arthroplasty cases. The news comes about two weeks after the company announced the launch of its next-gen Cori surgical system — a handheld robotics platform available for knee surgeries.

Read the full story.

3. More digital health support for people with kidney failure

Baxter and Ayogo Health are expanding their partnership to support people with kidney disease. The partnership between Deerfield, Ill.-based Baxter and Vancouver, B.C.-based Ayogo will combine the latter’s LifePlan behavior-based digital platform with Baxter’s renal care expertise to build mobile apps and digital solutions to support kidney failure patients. “This is particularly important in the midst of the [COVID-19] pandemic, when it is critical to support patients with digital health tools that empower them to perform dialysis in the safety of their home, while staying connected with their healthcare team,” said Baxter renal care business GM Laura Angelini.

Read the full story.

2. Aetna accuses Conformis of trying to use patient’s lawsuit to compel coverage

Joint replacement implant maker Conformis (NSDQ:CFMS) is improperly using a Colorado man’s denial of benefits lawsuit to force Aetna to cover its customized knee implants, the health insurer recently argued in a federal court filing. Billerica, Mass.-based Conformis joined John Michael Schaub of Golden, Colo., in his lawsuit against Aetna, filed in May in U.S. District Court in Massachusetts. The lawsuit, according to Aetna’s lawyers, turns the federal Employee Retirement and Income Security Act on its head.

Read the full story.

1. Improving the COVID-19 testing situation

It would probably be an understatement to say that the U.S. has faced challenges when it comes to coronavirus testing — with a new Vanity Fair expose raising even more questions. Some of the most-read stories on MassDevice this week involve efforts to improve the situation.

The U.S. Dept. of Health and Human Services (HHS) and Defense Dept. (DoD), for example, announced a $7.6 million contract for COVID-19 testing from Hologic.

Meanwhile, Sorrento Therapeutics (NSDQ:SRNE) entered into a licensing agreement with Columbia University for its COVID-19 saliva diagnostic test. The rapid, one-step diagnostic test is designed to detect SARS-CoV-2 (the virus causing coronavirus) in as little as 30 minutes from a sample of saliva. Developed by a team at Columbia, the test will be marketed by San Diego–based Sorrento under the name “Covi-Trace.” It holds all testing materials in a single tube and requires no specialized laboratory equipment, making it deployable for point-of-care, on-site or potentially at-home testing. Sorrento plans to move rapidly to submit an emergency use authorization request to the FDA and prepare for full-scale production.

Read the full story about Sorrento.

Check out the previous week’s top stories>>

Filed Under: Business/Financial News, Diagnostics, Dialysis, Digital Health, Featured, Orthopedics, Wall Street Beat Tagged With: Aetna, Ayogo Health, Baxter, conformis, coronavirus, COVID-19, Dexcom, Hologic, MassDevice Top Five, Smith+Nephew, Sorrento Therapeutics

In case you missed it

  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance
  • Surgalign settles on OEM business sale, posts Q2 earnings miss
  • Alcon lowers its 2022 forecast amid strong dollar
  • Masimo beats Street in Q2 as healthcare business catches up
  • Senseonics stock is up as it sticks by revenue guidance
  • Butterfly Network asks judge to dismiss Fujifilm Sonosite IP suit
  • Stereotaxis stock down amid cloudy outlook
  • The 10 largest orthopedic device companies in the world
  • BD, Labcorp collaborate on flow cytometry-based diagnostics
  • NeuroOne submits special FDA 510(k) application for Evo sEEG electrode
  • Si-Bone grows sales 15% in Q2
  • FDA approves second IDE study for CereVasc eShunt
  • Nuwellis posts Q2 sales beat
  • Avanos Medical updates full-year revenue guidance on mixed-bag Q2 results
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • Conformis rises on in-line Q2 results

RSS From Medical Design & Outsourcing

  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]
  • New method of cardiac ablation used in first in-human trial for ventricular tachycardia
    A new cardiac ablation technique for patients with ventricular tachycardia (VT) has been used in its first in-human multicenter trial involving Mayo Clinic. The new process — needle ablation using in-catheter, heated, saline-enhanced, radio frequency (SERF) energy — creates lesion scars inside the heart muscle where life-threatening arrhythmias cause VT, Mayo Clinic said. Injecting heated saline… […]
  • AdvaMed pushes CMS for proposed TCET pathway rule this year
    The Advanced Medical Technology Association (AdvaMed) is asking the Centers for Medicare & Medicaid Services (CMS) to move fast on a new way to guarantee reimbursement for new medtech innovations. CMS repealed the Medicare Coverage of Innovative Technology (MCIT) program last year but promised to explore other options to improve the coverage process for access… […]

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy